Starpharma Holdings Ltd
ASX:SPL

Watchlist Manager
Starpharma Holdings Ltd Logo
Starpharma Holdings Ltd
ASX:SPL
Watchlist
Price: 0.35 AUD 1.45% Market Closed
Market Cap: AU$146.4m

Net Margin

-170.8%
Current
Improving
by 54.9%
vs 3-y average of -225.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-170.8%
=
Net Income
AU$-10m
/
Revenue
AU$5.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-170.8%
=
Net Income
AU$-10m
/
Revenue
AU$5.9m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Starpharma Holdings Ltd
ASX:SPL
146.4m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.9B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.5B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
39th
Based on 4 004 companies
39th percentile
-170.8%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Starpharma Holdings Ltd
Glance View

Market Cap
146.4m AUD
Industry
Pharmaceuticals

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.

SPL Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-170.8%
=
Net Income
AU$-10m
/
Revenue
AU$5.9m
What is Starpharma Holdings Ltd's current Net Margin?

The current Net Margin for Starpharma Holdings Ltd is -170.8%, which is above its 3-year median of -225.7%.

How has Net Margin changed over time?

Over the last 3 years, Starpharma Holdings Ltd’s Net Margin has increased from -329.7% to -170.8%. During this period, it reached a low of -371.6% on Jun 30, 2023 and a high of -79% on Dec 31, 2023.

Back to Top